Pharmaceuticals, Biotechnology and Life Sciences
The National Institute for Health and Care Excellence (NICE) announced Thursday that empagliflozin (Jardiance) is recommended for use as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.
As part of a collaborative working agreement between United Lincolnshire Hospitals NHS Trust and pharmaceutical company Boehringer Ingelheim, a new cardio-diabetic outpatient service has been launched to help reduce recurring heart attacks in people with diabetes.
Boehringer Ingelheim has announced new data from the pivotal Phase II Effisayil 1 trial, presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston.
Company announcement – No. 21/ 2021 Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and…
In particular, efforts to research potential COVID-19 related therapies were accelerated, Boehringer Ingelheim spent 3.7 billion EUR on R&D, 7% more than in the previous year
German independent research institute Biomed X announces has completed its first joint research project with Boehringer Ingelheim in the fields of neuroscience. The results of the project are transferred to Boehringer Ingelheim for further development.
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research Institute (DCRI) on a new trial, EMPACT-MI
Boehringer Ingelheim has bought Northern Biologics Inc., a wholly owned subsidiary of Northern LP, whose programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim’s position in cancer immunology,
-Boehringer Ingelheim is enrolling first patient to test nvestigational compound BI ENaC inhibitor delivered twice daily via the Respimat, a…
FDA has granted to Boehringer Ingelheim a breakthrough therapy designation for Ofev, for Chronic Fibrosing ILDs with a Progressive Phenotype, after the study results from the Phase III testing met its primary endpoint and was recently published in the New England Journal of Medicine.